Next, exploring the interplay between EGFR and KRAS and investigating how EGFR-combined KRAS mutations impact the efficacy and resistance of EGFR molecular inhibitors in lung adenocarcinoma was the primary goal of Cluster 3 (39, 40). Here, KRAS is linked to lung adenocarcinoma.